| Literature DB >> 36042619 |
Hyung-Hoon Oh1, Sung-Bum Cho1, Ji-Yun Hong1, Dong-Hyun Kim1, Hee-Chan Yang2, Sang-Wook Kim2, Jun Lee3, Seong-Jung Kim3, Yeom-Dong Han4, Geom-Seok Seo4, Gun-Young Hong5, Ho-Dong Kim6, Dae-Seong Myung1, Hyun-Soo Kim1, Young-Eun Joo1.
Abstract
Self-expandable metal stent (SEMS) placement is commonly used for palliation of left-sided malignant colorectal obstruction (MCO). However, right-sided MCO is usually treated surgically. Recent studies that compared palliative SEMS insertion and emergency surgery in right-sided MCOs have reported conflicting results. This study aimed to compare the effectiveness of palliative SEMS placement in left-sided MCOs and right-sided MCOs and to investigate the predictive factors for clinical success and risk factors for complications. Data from 469 patients who underwent palliative SEMS placement for MCO at 6 hospitals in the Honam province of South Korea between 2009 and 2018 were reviewed. Among them, 69 patients with right-sided MCO and 400 patients with left-sided MCO who underwent SEMS placement for palliative purposes were enrolled. Clinical success, overall survival, complications, and predictive factors for clinical success and risk factors for complications were included as the main outcome measures. The clinical success rates were 97.1% (65/67) in right-sided MCO patients and 88.2% (353/400) in left-sided MCO patients. Complications including stent migration, tumor ingrowth, outgrowth, perforation, bacteremia/fever, and bleeding occurred in 10.1% (7/69) of right-sided MCO patients and 19.9% (79/400) of left-sided MCO patients. The mean overall survival of right-sided MCO was 28.02 months and 18.23 months for left-sided MCO. In multivariate logistic regression analysis, T3 stage tumors and the use of uncovered stents were significant factors for the clinical success of SEMS. The use of covered stents and performance status score of 0 to 2 were independent significant risk factors for complications. Palliative SEMS placement in right-sided MCO showed better clinical success rates than left-sided MCO. The use of uncovered stents is recommended for higher clinical success rates and lower complication rates.Entities:
Mesh:
Year: 2022 PMID: 36042619 PMCID: PMC9410579 DOI: 10.1097/MD.0000000000030156
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristics of enrolled patients.
| Variable | Right-sided (n = 69) | Left-sided (n = 400) | ||
|---|---|---|---|---|
| Age (yr) | Mean ± SD | 69.8 ± 14.2 | 68.3 ± 13.1 | .407 |
| Gender | Male | 31 (44.9%) | 165 (41.3%) | .567 |
| Female | 38 (55.1%) | 235 (58.7%) | ||
| BMI (SD), kg/m2 | Mean ± SD | 22.0 ± 3.3 | 21.6 ± 3.2 | .412 |
| PS score | 0–2 | 52 (75.4%) | 305 (76.3%) | .873 |
| 3–4 | 17 (24.6%) | 95 (23.8%) | ||
| Abdominal operation history | 18 (26.1%) | 90 (22.5%) | .513 | |
| Tumor location | Ascending 16 (23.2%) | Splenic flexure 32 (8.0%) | ||
| Hepatic flexure 28 (40.6%) | Descending 17 (4.3%) | |||
| Transverse 25 (36.2%) | SD junction 22 (5.5%) | |||
| Sigmoid colon 147 (36.8%) | ||||
| Rectosigmoid junction 120 (30.0%) | ||||
| Rectum 62 (15.5%) | ||||
| Length of obstruction (mm) | Mean ± SD | 37.6 ± 11.2 | 37.0 ± 13.1 | .562 |
| Complete obstruction | 50 (72.5%) | 283 (70.6%) | .772 | |
| T (n = 103) | T3 | 8 (47.1%) | 57 (66.3%) | .133 |
| T4 | 9 (52.9%) | 29 (33.7%) | ||
| N (n = 108) | N0 | 1 (5.6%) | 18 (20.0%) | .476 |
| N1 | 8 (44.4%) | 31 (34.4%) | ||
| N2 | 9 (50.0%) | 40 (44.4%) | ||
| N4 | 0 (0%) | 1 (1.1%) | ||
| Metastasis | 61 (88.4%) | 371 (92.8%) | .216 | |
| Uncovered stent | 49 (71.0%) | 271 (67.8%) | .591 | |
| Length of stent | 84.9 ± 16.6 | 86.7 ± 17.3 | .410 |
BMI = body mass index, PS score = performance status score, SD = standard deviation.
Clinical outcomes and details of complications after SEMS placement.
| Variable | Overall | Right-sided | Left-sided | |
|---|---|---|---|---|
| Clinical success | 420/469 (89.6) | 67 (97.1) | 353 (88.2) | .026 |
| Complication | 86 (18.3) | 7 (10.1) | 79 (19.9) | .057 |
| Acute complication (before 15 d) | 30 (6.4) | 1 (1.4) | 29 (7.2) | .069 |
| Delayed complication (after 15 d) | 61 (13.0) | 6 (8.7) | 55 (13.8) | .249 |
| Stent migration | 31 (6.6) | 1 (1.4) | 30 (7.5) | .062 |
| Stent ingrowth | 27 (5.8) | 4 (5.8) | 23 (5.8) | .988 |
| Stent outgrowth | 9 (1.9) | 2 (2.9) | 7 (1.8) | .521 |
| Perforation | 20 (4.3) | 0 | 20 (5.0) | .058 |
| Bacteremia/fever | 4 (0.9) | 0 | 4 (1.0) | .404 |
| Bleeding | 0 (0.2) | 0 | 1 (0.3) | .678 |
| Operation after stent | 138 (29.4) | 21 (30.4) | 117 (29.3) | .842 |
SEMS = self-expandable metal stent.
Figure 1.Comparison of overall survival based on location of MCOs. Mean follow-up time for right-sided MCO was 15.31 ± 13.80 mo and left-sided MCO was 18.49 ± 20.10 mo. The mean overall survival of right-sided MCO was 28.02 months (95% CI: 16.75–39.29) and left-sided MCO was 18.23 mo (95% CI: 14.61–21.85) (P = .095). CI = confidence interval, MCO = malignant colorectal obstruction.
Univariate and multivariate analyses of the predictive factors of clinical success.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95% CI | OR | 95% CI | ||
| Age | 1.000 | 0.978–1.023 | .999 | |||
| Gender, male | 1.050 | 0.577–1.910 | .873 | |||
| BMI (SD), kg/m2 | 1.070 | 0.967–1.183 | .190 | |||
| Hypertension | 0.962 | 0.529–1.749 | .898 | |||
| Diabetes mellitus | 2.038 | 0.841–4.937 | .115 | |||
| PS score (0–2) | 0.761 | 0.393–1.472 | .417 | |||
| Abdomen operation history, yes | 1.187 | 0.572–2.465 | .646 | |||
| Tumor location (right) | 4.460 | 1.058–18.807 | .042 | 1.477 | 0.125–17.465 | .757 |
| Tumor location (flexure) | 1.057 | 0.430–2.602 | .903 | |||
| Length of obstruction (mm) | 0.960 | 0.937–0.985 | .001 | 0.961 | 0.906–1.018 | .175 |
| T3 versus T4 | 4.762 | 0.878–25.641 | .070 | 8.475 | 1.353–52.632 | .022 |
| M stage | 1.042 | 0.353–3.078 | .940 | |||
| Peritoneal carcinomatosis | 1.477 | 0.771–2.832 | .240 | |||
| Uncovered stent | 3.295 | 1.801–6.027 | .000 | 9.109 | 1.463–56.715 | .018 |
| Length of stent (mm) | 0.992 | 0.976–1.009 | .373 | |||
BMI = body mass index, CI = confidence interval, OR = odds ratio, PS score = performance status score, SD = standard deviation.
Univariate and multivariate analyses of the risk factors of complication.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95% CI | OR | 95% CI | ||
| Age | 0.988 | 0.971–1.005 | 0.179 | |||
| Gender, male | 0.746 | 0.466–1.194 | 0.222 | |||
| BMI (SD), kg/m2 | 0.998 | 0.927–1.076 | 0.965 | |||
| PS score (0–2) | 2.179 | 1.136–4.179 | 0.019 | 2.466 | 1.257–4.839 | .009 |
| Abdomen operation history | 0.791 | 0.442–1.413 | 0.428 | |||
| Tumor location (left) | 2.180 | 0.961–4.946 | 0.062 | 2.145 | 0.926–4.970 | .075 |
| Tumor location (flexure) | 0.761 | 0.359–1.612 | 0.476 | |||
| Length of obstruction (mm) | 1.006 | 0.985–1.028 | 0.566 | |||
| T4 versus T3 | 1.753 | 0.664–4.627 | 0.257 | |||
| Metastasis | 1.477 | 0.558–3.908 | 0.432 | |||
| Peritoneal carcinomatosis | 1.052 | 0.648–1.708 | 0.837 | |||
| Covered stent | 3.126 | 1.934–5.053 | 0.000 | 3.035 | 1.842–5.002 | <.001 |
| Length of stent (mm) | 1.012 | 0.999–1.025 | 0.071 | 1.009 | 0.994–1.023 | .242 |
BMI = body mass index, CI = confidence interval, OR = odds ratio, PS score = performance status score, SD = standard deviation.
PS score and details of complications after SEMS placement.
| Variable | Overall | PS score 0 to 2 | PS score 3 to 4 | |
|---|---|---|---|---|
| Complication | 86 (18.3) | 74 (20.7) | 12 (10.7) | .017 |
| Stent migration | 31 (6.6) | 29 (8.1) | 2 (1.8) | .019 |
| Stent ingrowth | 27 (5.8) | 21 (5.9) | 6 (5.4) | .835 |
| Stent outgrowth | 9 (1.9) | 8 (2.2) | 1 (0.9) | .364 |
| Perforation | 20 (4.3) | 18 (5.0) | 2 (1.8) | .137 |
| Bacteremia/fever | 4 (0.9) | 3 (0.8) | 1 (0.9) | .958 |
| Acute complication (before 15 d) | 30 (6.4) | 22 (6.2) | 8 (7.1) | .711 |
PS score = performance status score, SEMS = self-expandable metal stent.